Prednisone News and Research

RSS

Health Canada grants market authorization for Sanofi-aventis Jevtana to treat prostate cancer

Sanofi-aventis announced today that Health Canada has granted market authorization for Jevtana injection in combination with prednisone for the treatment of patients with metastatic castration resistant prostate cancer, previously treated with a docetaxel-containing treatment regimen.

24 Jun 2011

Allos Therapeutics reports results from FOLOTYN pivotal trial against peripheral T-cell lymphoma

Allos Therapeutics, Inc. today reported results from a retrospective analysis of data from the Company's pivotal PROPEL trial which suggested that treatment with single-agent FOLOTYN may result in increased response rates and progression-free survival relative to the immediate prior line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.

17 Jun 2011

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

Celgene International Sàrl announced that clinical data from two studies evaluating the use of REVLIMID® (lenalidomide) with standard R-CHOP chemotherapy in patients with untreated diffuse large B cell (DLBCL) or grade 3 follicular lymphoma were presented at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland.

17 Jun 2011

Positive results from etanercept pilot study against dermatomyositis

A multicenter pilot study of etanercept for treatment of dermatomyositis found no major safety concerns and many patients treated with the drug were successfully weaned from steroid therapy.

17 Jun 2011

Initial data from COMPLETE study on peripheral T-cell lymphoma presented at ICML 2011

Allos Therapeutics, Inc. today announced the presentation of initial data from COMPLETE, an international registry designed to address the urgent need for an increased understanding of the treatment patterns and outcomes for patients with peripheral T-cell lymphoma.

16 Jun 2011

NYU Cancer Institute scientists present new research findings at ASCO 2011

Experts from The Cancer Institute, an NCI-designated cancer center, at NYU Langone Medical Center presented new research findings at the 47th American Society of Clinical Oncology (ASCO) 2011 Annual Meeting in Chicago, IL.

8 Jun 2011

Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

Celgene International Sàrl today announced results from a phase II investigator initiated study of REVLIMID (lenalidomide) in combination with Avastin (bevacizumab), docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, Ill.

6 Jun 2011

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Bristol-Myers Squibb Company today announced results from a second Phase 3 randomized, double blind study demonstrating that YERVOY (ipilimumab) prolonged the lives of patients with metastatic melanoma.

6 Jun 2011

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Bristol-Myers Squibb Company announced today it has entered in to a clinical collaboration agreement with Roche to evaluate the utility of Bristol-Myers Squibb's CTLA-4 inhibitor, YERVOY (ipilimumab), in combination with Roche's investigational oral BRAF inhibitor, vemurafenib, in treating patients with a specific type of metastatic melanoma.

4 Jun 2011

ZYTIGA clinical study data on prostate cancer to be presented at ASCO 2011

Data related to ZYTIGA (abiraterone acetate) will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

3 Jun 2011

Abiraterone acetate effective for men with advanced prostate cancer

A drug recently approved by the Food & Drug Administration for the treatment of prostate cancer is proving to give some patients the gift of time. A new study shows abiraterone acetate extends the lives of men with the most advanced form of the disease by about four months.

27 May 2011

NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer

A study titled "Abiraterone and Increased Survival in Metastatic Prostate Cancer," published in the May 26 issue of NEJM, found that patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel showed a significant improvement in overall survival when treated with ZYTIGA plus prednisone compared to patients treated with prednisone plus placebo.

26 May 2011

African Americans with SLE have higher antibody response to influenza vaccination: Study

New research shows that African Americans with systemic lupus erythematosus had a higher antibody response to influenza vaccination than European American patients.

21 May 2011

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

Amgen today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended a positive opinion for the marketing authorization of XGEVA (denosumab) for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumors.

20 May 2011

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

Amgen today announced primary results of a pivotal Phase 3 trial demonstrating that XGEVA significantly increased bone metastasis-free survival for more than four months in men with castrate-resistant metastatic prostate cancer that has not yet spread to bone.

18 May 2011

Allos, Mundipharma enter strategic collaboration to co-develop FOLOTYN

Allos Therapeutics, Inc. and Mundipharma International Corporation Limited today jointly announced that the companies have entered into a strategic collaboration agreement to co-develop FOLOTYN (pralatrexate injection).

11 May 2011

When Government usurps responsibility, people are more likely to abdicate

We hear much talk about preventive care, but nobody has defined it. From the content of the discussions, I deduce that what the health bureaucrats actually refer to would be better characterized as “early detection.” Early detection is what occurs when a physician finds a disease in its early stages that might have been prevented by earlier measures. But who can take those measures? Not the physician, only the patient. There is only one person living the patient’s life; it is the patient. I cannot live his life for him.

9 May 2011

Centocor Ortho Biotech receives FDA approval for Zytiga to treat prostate cancer

The U.S. Food and Drug Administration today approved Zytiga in combination with prednisone to treat patients with late-stage castration-resistant prostate cancer who have received prior docetaxel.

28 Apr 2011

Positive results from Sanofi-aventis and Regeneron ZALTRAP Phase III study in mCRC

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced that the Phase III VELOUR trial evaluating the investigational agent ZALTRAP, also known as VEGF Trap, in combination with the FOLFIRI chemotherapy regimen versus a regimen of FOLFIRI plus placebo met its primary endpoint of improving overall survival in the second-line treatment of metastatic colorectal cancer.

27 Apr 2011

Millennium submits two VELCADE sNDAs to FDA

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that it has submitted two supplemental new drug applications (sNDAs) for VELCADE® (bortezomib) for Injection to the U.S. Food and Drug Administration. The first application seeks to add a subcutaneous route of administration for VELCADE. The second application is for the use of VELCADE in combination with rituximab in patients with relapsed follicular non-Hodgkin lymphoma (NHL).

26 Apr 2011

Prednisone News and Research

Health Canada grants market authorization for Sanofi-aventis Jevtana to treat prostate cancer

Allos Therapeutics reports results from FOLOTYN pivotal trial against peripheral T-cell lymphoma

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

Positive results from etanercept pilot study against dermatomyositis

Initial data from COMPLETE study on peripheral T-cell lymphoma presented at ICML 2011

NYU Cancer Institute scientists present new research findings at ASCO 2011

Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

ZYTIGA clinical study data on prostate cancer to be presented at ASCO 2011

Abiraterone acetate effective for men with advanced prostate cancer

NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer

African Americans with SLE have higher antibody response to influenza vaccination: Study

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

Allos, Mundipharma enter strategic collaboration to co-develop FOLOTYN

When Government usurps responsibility, people are more likely to abdicate

Centocor Ortho Biotech receives FDA approval for Zytiga to treat prostate cancer

Positive results from Sanofi-aventis and Regeneron ZALTRAP Phase III study in mCRC

Millennium submits two VELCADE sNDAs to FDA

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News